GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma
Unknown status
Tom Baker Cancer Centre
Phase 1/Phase 2
Objective of study: To evaluate the safety and efficacy of infusional gemcitabine prior to
HDM (high-dose melphalan) as HDCT (High Dose Chemotherapy) followed by autologous stem cell
transplantation in patients with relapsed/refractory lymphoma.
GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma
Unknown status
AHS Cancer Control Alberta
Phase 1/Phase 2
Objective of study: To evaluate the safety and efficacy of infusional gemcitabine prior to
HDM (high-dose melphalan) as HDCT (High Dose Chemotherapy) followed by autologous stem cell
transplantation in patients with relapsed/refractory lymphoma.
Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
Completed
Novartis Pharmaceuticals
Phase 1
To determine the MTD/RP2D of the HDM201 and LEE011 combination and evaluate whether the
combination is safe and has beneficial effects in patients with liposarcoma.
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
Active, not recruiting
Novartis Pharmaceuticals
Phase 1
This study is to characterize the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in
combination with HDM201 in patients with metastatic uveal melanoma.
Next Generation Personalized Neuroblastoma Therapy
Recruiting
Foundation Medicine
Phase 1
The purpose of this research study is to match genomic aberrations in tumor cells at time of
relapse to rationally designed combinations of molecularly targeted agents. This study will
be done in two parts:
Part I: Tumor will be accessed at study entry via a biopsy and subjected to deep sequencing
to identify protocol-specified biomarkers for therapy assignment.
Part II: If the tumor contains a genetic change defined by the study as being actionable, and
other criteria are met, participants will be assigned to therapy based upon the genetic
changes identified in the tumor biopsy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
